8 research outputs found

    Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries.

    Get PDF
    BACKGROUND: As global initiatives increase patient access to surgical treatments, there remains a need to understand the adverse effects of surgery and define appropriate levels of perioperative care. METHODS: We designed a prospective international 7-day cohort study of outcomes following elective adult inpatient surgery in 27 countries. The primary outcome was in-hospital complications. Secondary outcomes were death following a complication (failure to rescue) and death in hospital. Process measures were admission to critical care immediately after surgery or to treat a complication and duration of hospital stay. A single definition of critical care was used for all countries. RESULTS: A total of 474 hospitals in 19 high-, 7 middle- and 1 low-income country were included in the primary analysis. Data included 44 814 patients with a median hospital stay of 4 (range 2-7) days. A total of 7508 patients (16.8%) developed one or more postoperative complication and 207 died (0.5%). The overall mortality among patients who developed complications was 2.8%. Mortality following complications ranged from 2.4% for pulmonary embolism to 43.9% for cardiac arrest. A total of 4360 (9.7%) patients were admitted to a critical care unit as routine immediately after surgery, of whom 2198 (50.4%) developed a complication, with 105 (2.4%) deaths. A total of 1233 patients (16.4%) were admitted to a critical care unit to treat complications, with 119 (9.7%) deaths. Despite lower baseline risk, outcomes were similar in low- and middle-income compared with high-income countries. CONCLUSIONS: Poor patient outcomes are common after inpatient surgery. Global initiatives to increase access to surgical treatments should also address the need for safe perioperative care. STUDY REGISTRATION: ISRCTN5181700

    Have lichenized fungi delivered promising anticancer small molecules?

    No full text
    This review, covering the literature from 1844 to present (end 2017), probes questions concerning small molecule metabolites derived from lichens (lichenized fungi) and their impact in terms of providing compounds with significant promise in oncology. The review gives an overview of lichenized fungi and summarizes the classes of compounds obtained as metabolites from these organisms. A definition of what characteristics an actual “promising” anticancer compound should possess is also delineated. The review reports a brief overview on human cancer and then goes into depth in listing compounds with so-called “anticancer properties” that have been isolated from lichenized fungi, according to their small molecule structural classes. Five “most promising” compounds are discussed in-depth, also considering the possibility of obtaining sufficient amounts for further investigations

    Teratogens

    No full text

    Have lichenized fungi delivered promising anticancer small molecules?

    No full text

    Kuluttajabarometri maakunnittain 2000, 2. neljännes

    Get PDF
    Suomen virallinen tilasto (SVT

    Use of failure-to-rescue to identify international variation in postoperative care in low-, middle- and high-income countries: a 7-day cohort study of elective surgery

    Get PDF
    This was an investigator-initiated study funded by Nestle Health Sciences through an unrestricted research grant and by a National Institute for Health Research (UK) Professorship held by R.P. The study was sponsored by Queen Mary University of London
    corecore